Recombinant Leishmania antigens for serodiagnosis of visceral leishmaniasis

Clinical and Diagnostic Laboratory Immunology

Volumn 12, Issue 10, 2005, Pages 1164-1167

  Passos, S ^a   Carvalho, L P ^a   Orge, G ^a   Jeronimo S M ^b   Bezerra, G ^c   Soto, M ^d   Alonso, C ^d   Carvalho, E M ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^c FEDERAL UNIVERSITY OF MARANHÃO   (Brazil)

^d CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BIOCHEMICAL MARKER; IMMUNOGLOBULIN G; LEISHMANIA ANTIGEN; PROTOZOON ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN DETECTION; ARTICLE; BONE MARROW BIOPSY; DISEASE ACTIVITY; GENETIC RECOMBINATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTOZOAL INFECTION; SERODIAGNOSIS; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; HUMANS; IMMUNOGLOBULIN G; LEISHMANIA; LEISHMANIASIS, VISCERAL; MEMBRANE GLYCOPROTEINS; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS;

EID: 26944434767     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.12.10.1164-1167.2005     Document Type: Article

References (13)

1. Boelaert, M., B. Criel, J. Leeuwenburg, W. Van Damme, D. Le Ray, and P. Van der Stuyft. 2000. Visceral leishmaniasis control: a public health perspective. Trans. R. Soc. Trop. Med. Hyg. 94:465-471.
2. Braz, R. F., E. T. Nascimento, D. R. Martins, M. E. Wilson, R. D. Pearson, S. G. Reed, and S. M. Jeronimo. 2002. The sensitivity and specificity of Leishmania chagasi recombinant K39 antigen in the diagnosis of American visceral leishmaniasis and in differentiating active from subclinical infection. Am. J. Trop. Med. Hyg. 67:344-348.
3. Carvalho, E. M., R. Badaro, S. G. Reed, T. C. Jones, and W. D. Johnson, Jr. 1985. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J. Clin. Investig. 76:2066-2069.
4. Carvalho, E. M., A. Barral, D. Pedral-Sampaio, M. Barral-Netto, R. Badaro, H. Rocha, and W. D. Johnson, Jr. 1992. Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J. Infect. Dis. 165:535-540.
5. Desjeux, P. 1996. Leishmaniasis. Public health aspects and control. Clin. Dermatol. 14:417-423.
6. Evans, T. G., M. J. Teixeira, I. T. McAuliffe, I. Vasconcelos, A. W. Vasconcelos, A. Sousa Ade, J. W. Lima, and R. D. Pearson. 1992. Epidemiology of visceral leishmaniasis in northeast Brazil. J. Infect. Dis. 166:1124-1132.
7. Fuertes, M. A., J. M. Perez, M. Soto, M. C. Lopez, and C. Alonso. 2001. Calcium-induced conformational changes in Leishmania infantum kineto-plastid membrane protein-11. J. Biol. Inorg. Chem. 6:107-117.
8. Miles, S. A., S. M. Conrad, R. G. Alves, S. M. Jeronimo, and D. M. Mosser. 2005. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J. Exp. Med. 201:747-754.
9. Reed, S. G. 1996. Diagnosis of leishmaniasis. Clin. Dermatol. 14:471-478.
10. Soto, M., J. M. Requena, L. Quijada, and C. Alonso. 1998. Multicomponent chimeric antigen for serodiagnosis of canine visceral leishmaniasis. J. Clin. Microbiol. 36:58-63.
11. World Health Organization. 1990. Control of the leishmaniasis, p. 1-158. Technical report series no. 793. World Health Organization, Geneva, Switzerland.
12. World Health Organization. 2002. Strategic direction: leishmaniasis. World Health Organization, Geneva, Switzerland.
13. Zijlstra, E. E. 1992. The treatment of kala-azar: old and new options. Trop. Geogr. Med. 44:288.